Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia
SHANGHAI,March 17,2025--Rona Therapeutics Inc.,a global leader in RNA-targeted therapeutics,announced the clearance of an Investigational New Drug (IND) by the U.S. Food and Drug Administration (FDA)